[Non-small cell lung cancer: HER2 oncogene status]

Area of Science:

• Oncology
• Molecular Pathology

Context:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
• HER2 protein and gene alterations are implicated in various cancers, but their role in NSCLC requires further elucidation.
• Understanding HER2 heterogeneity is crucial for targeted therapy selection.

Purpose:

• To investigate the expression and gene status of HER2 in non-small cell lung cancer.
• To assess the heterogeneity of HER2 protein and gene alterations within NSCLC tumors.
• To correlate HER2 protein levels with gene amplification status.

Summary:

• 218 NSCLC samples were analyzed for HER2 protein (immunohistochemistry) and HER2 gene/CEP17 (in situ hybridization).
• HER2 protein positivity was observed in 27% of cases, with 30% showing intratumor heterogeneity.
• HER2 gene amplification occurred in 6% of cases, with a moderate correlation between protein status and gene amplification (r=0.38).

Impact:

• Findings indicate that elevated HER2 protein levels are present in a significant subset of NSCLC.
• HER2 gene amplification is less common but can occur, potentially driving enhanced protein synthesis.
• The study highlights the importance of evaluating both HER2 protein and gene status, considering potential heterogeneity, for personalized NSCLC treatment strategies.